Objective: This study aimed to evaluate the effects of transdermal testosterone administration on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). Materials and Method: Sixty-two male patients with Ageing Male Symptom Questionnaire (AMS-Q) scores over 27 and a total serum testosterone level below 350 ng/dl (12.1 nmol/l) who presented to our urology clinic with complaints of LUTS and ED, were enrolled in this study. Uroflowmetry and the International Prostate Symptom Scale were used to evaluate the severity of LUTS. The International Index of Erectile Function was used to detect the severity of ED. In addition, the AMS-Q was used to quantify the severity of hypogonadism. We randomly divided patients into 2 groups. Thirty-one patients in the first group had transdermal testosterone administered at a daily dose of 50 mg (a sachet of 5 g) on the skin for 3 months. In the second group, 31 patients had a placebo administered for 3 months. The scales were recompleted based on interviews and uroflowmetry was repeated during checks of the patients performed in the first and third months. Results: We detected a decrease in AMS-Q scores and an increase in maximum uroflow rate values and the International Index of Erectile Function scores in the first group compared with the placebo group. Although a decrease was detected in post-treatment International Prostate Symptom Scale scores in the first group, it was not regarded as statistically significant. Conclusion: This study revealed that testosterone replacement therapy is effective in improving LUTS and ED symptoms.

Abrams P, Griffiths D, Hofner K, Liao L, Schäfer W, Tubaro A: The urodynamic assessment of low urinary symptoms (committee 7); in: Chatelain C, Denis L, Foo KT, Khoury S, McConnell J (eds): Benign Prostatic Hyperplasia 5th International Consultation on BPH. 2001, pp227-282.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A: The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
Ameda K, Sullivan MP, Bae RJ, Yalla SV: Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 1999;162:142-146.
Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978- 2984.
Buvat J, Lemaire A: Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997;158:1764-1767.
Lee JH, Kim Y, Park YW, Lee DG: Relationship between benign prostatic hyperplasia/ lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men. J Sex Med 2014;11:1309- 1315.
Kalyani RR, Dobs AS: Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14:226-234.
Dandona P, Rosenberg MT: A practical guide to male hypogonadism in the primary case setting. Int J Clin Pract 2010;64:682-696.
Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, Prins GS: Location and concentration of estrogen, progesterone and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 1995;14:87-96.
Keast JR: The autonomic nerve supply of male sex organs-an important target of circulating androgens. Behav Brain Res 1995;105: 81-92.
Mohr BA, Guay AT, O'Donnell AB, McKinlay JB: Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2005;62:64-73.
Hollander N, Hollander VP: The microdetermination of testosterone in human spermatic vein blood. J Clin Endocrinol Metab 1958; 18:966-971.
Kaufman JM, Giri M, Deslypere JM, Thomas G, Vermeulen A: Influence of age on the responsiveness of the gonadotrophs to luteinizing hormone releasing hormone in males. J Clin Endocrinol Metab 1991;72:1255-1260.
T'Sjoen G, Goemaere S, De Meyere M, Kaufman JM: Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004;29:201-214.
Onem K, Kadıoglu A, Tellaloglu S: Prevalence study of late onset hypogonadism in Turkey. Dialog Endocrinol 2007;4:300.
Miwa Y, Kaneda T, Yokoyama O: Correlation between the aging males' symptoms scale and sex steroids, gonadotropins, dihydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med 2006;3: 723-726.
Schaltzl G, Madersbacher S, Temml C, Krenn SK, Nader A, Sregi G, Lapin A, Hermann M, Berger P, Marberger M: Serum androgen levels in men: impact of health status and age. Urology 2003;61:629-633.
Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB: An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston area community health survey. BJU Int 2007;100:321-326.
Holmang S, Marin P, Lindstedt G, Hedelin H: Effect of long term oral testosteronundecanoate treatment on prostate volume and serum prostate specific antigen concentration in eugonadal middle aged men. Prostate 1993; 23:99-106.
Kohn TP, Mata DA, Ramasamy R, Lipshultz LI: Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol 2016;69:1083-1090.
Shiri R, Häkkinen J, Koskimäki J, Hakama M, Tammela TL, Auvinen A: Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. Int J Impot Res 2007;19:317-320.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.